SG11202008149RA - Anti cd6 antibodies for treating severe asthma - Google Patents

Anti cd6 antibodies for treating severe asthma

Info

Publication number
SG11202008149RA
SG11202008149RA SG11202008149RA SG11202008149RA SG11202008149RA SG 11202008149R A SG11202008149R A SG 11202008149RA SG 11202008149R A SG11202008149R A SG 11202008149RA SG 11202008149R A SG11202008149R A SG 11202008149RA SG 11202008149R A SG11202008149R A SG 11202008149RA
Authority
SG
Singapore
Prior art keywords
antibodies
severe asthma
treating severe
treating
asthma
Prior art date
Application number
SG11202008149RA
Other languages
English (en)
Inventor
Stephen Connelly
Cherie Ng
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of SG11202008149RA publication Critical patent/SG11202008149RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202008149RA 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma SG11202008149RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (1)

Publication Number Publication Date
SG11202008149RA true SG11202008149RA (en) 2020-09-29

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008149RA SG11202008149RA (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Country Status (13)

Country Link
US (1) US20210380711A1 (ko)
EP (1) EP3759140A1 (ko)
KR (1) KR20200128415A (ko)
CN (1) CN112424226A (ko)
AU (1) AU2019228508A1 (ko)
BR (1) BR112020017445A2 (ko)
CA (1) CA3091920A1 (ko)
IL (1) IL276875A (ko)
MX (1) MX2020008916A (ko)
PH (1) PH12020551323A1 (ko)
SG (1) SG11202008149RA (ko)
WO (1) WO2019169015A1 (ko)
ZA (1) ZA202005320B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
PL3024485T3 (pl) 2013-07-23 2021-06-14 Biocon Limited Zastosowanie partnera wiążącego cd6 i oparty na tym sposób
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
EP4255452A1 (en) * 2020-12-04 2023-10-11 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eef cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
WO1998043089A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
EP2119453B1 (en) 2006-12-26 2015-05-20 Centro de Inmunolgía Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2018073721A1 (en) * 2016-10-18 2018-04-26 Biocon Limited Use of itolizumab to reduce phosphorylation of cd6

Also Published As

Publication number Publication date
BR112020017445A2 (pt) 2021-01-26
US20210380711A1 (en) 2021-12-09
CA3091920A1 (en) 2019-09-06
PH12020551323A1 (en) 2021-04-26
EP3759140A1 (en) 2021-01-06
RU2020130563A (ru) 2022-03-28
WO2019169015A1 (en) 2019-09-06
MX2020008916A (es) 2021-02-15
AU2019228508A1 (en) 2020-09-17
ZA202005320B (en) 2022-02-23
CN112424226A (zh) 2021-02-26
RU2020130563A3 (ko) 2022-04-01
JP2021515039A (ja) 2021-06-17
KR20200128415A (ko) 2020-11-12
IL276875A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL285496A (en) Methods for treating biliary obstruction
ZA202005320B (en) Anti cd6 antibodies for treating severe asthma
GB2602429B (en) Systems for Treating Neurological Conditions
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
IL277861A (en) Antibodies specific to AXL for cancer treatment
IL281449A (en) Anti-ifnar1 antibodies for the treatment of autoimmune diseases
IL280128A (en) A method for treating epilepsy
IL282756A (en) Humanized antibodies against SIRPα
IL287907A (en) Cancer treatment methods
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3448365A4 (en) CONSTIPATION TREATMENT METHOD
EP3990022A4 (en) Anti-cd33 antibodies for treating cancer
EP3820461A4 (en) METHODS OF TREATMENT OF CANCER
EP3894561A4 (en) CANCER TREATMENT METHODS
SG11202010528XA (en) Combinations for treating cancer
IL308393A (en) Antibodies for the treatment of alpha-synuclein diseases
IL289842A (en) Human anti-liv1 antibodies for cancer therapy
IL277056A (en) Methods for purifying antibodies
GB201818618D0 (en) Monoclonal antibodies against ambra-1
IL290262A (en) Antibodies against bdca-2
IL289018A (en) Methods for treating neurodegenerative disorders
IL280424A (en) Methods for treating neurodegenerative disorders
IL278921A (en) Combined treatments for cancer
EP3762497A4 (en) METHODS OF TREATMENT OF VEGF-ASSOCIATED DISEASES
EP3801497A4 (en) METHOD OF TREATMENT OF NON-COMPACTION CARDIOMYOPATHY